Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is pursuing a two-pronged approach to combat neurological disorders that affect hundreds of millions globally. The company's pipeline targets multiple sclerosis (MS) and the acute effects of alcohol intoxication, two areas where current treatments often fall short.
Multiple sclerosis, a debilitating autoimmune disease affecting the central nervous system, impacts an estimated 2.9 million people worldwide, with about one million cases in the United States. The disease is typically diagnosed between ages 20 and 50, with a mean age of 32 globally, and affects women at roughly twice the rate of men. Quantum BioPharma's lead candidate for MS is Lucid-MS, a patented new chemical entity that takes a fundamentally different approach from existing therapies. Lucid-MS is designed to promote remyelination and protect neurons, potentially reversing damage rather than merely managing symptoms. The company is currently supporting phase 2 development of Lucid-MS through an ongoing imaging collaboration with Massachusetts General Hospital.
In addition to its MS program, Quantum BioPharma developed unbuzzd, a proprietary dietary supplement formulated to support alcohol metabolism and reduce the acute effects of intoxication and hangover. This product addresses the widespread issue of alcohol-related cognitive impairment and physiological stress. Unbuzzd is available as an over-the-counter supplement, providing a non-prescription option for individuals seeking to mitigate the impact of alcohol consumption.
The company's dual strategy highlights its commitment to addressing significant neurological needs. Lucid-MS represents a potential breakthrough for MS patients who have limited options for disease modification, while unbuzzd targets a common but often overlooked aspect of public health. Both programs leverage Quantum BioPharma's expertise in neurology and biochemistry.
For more information on Quantum BioPharma and its pipeline, visit the company's newsroom at https://ibn.fm/QNTM. The full terms of use and disclaimers are available at http://IBN.fm/Disclaimer.
